High-fat diet-induced alterations in the feeding suppression of low-dose nisoxetine, a selective norepinephrine reuptake inhibitor

Journal of Obesity

Volumn 2013, Issue , 2013, Pages

  Bello, Nicholas T ^a,b   Walters, Amy L ^a   Verpeut, Jessica L ^a,b   Cunha, Priscila P ^a  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NISOXETINE; NORADRENALIN UPTAKE INHIBITOR; PROTEIN C FOS; DRUG DERIVATIVE; FLUOXETINE; NORADRENALIN;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ARCUATE NUCLEUS; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; FEEDING BEHAVIOR; FOOD INTAKE; HEART RATE; HEMODYNAMICS; HYPOTHALAMUS; HYPOTHALAMUS NUCLEUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIPID DIET; LOCUS CERULEUS; LOW DRUG DOSE; MALE; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE; WEIGHT GAIN; ANIMAL; BLOOD PRESSURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; EATING; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; APPETITE REGULATION; ARCUATE NUCLEUS; BLOOD PRESSURE; DIET, HIGH-FAT; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; FLUOXETINE; HEART RATE; IMMUNOHISTOCHEMISTRY; MALE; NOREPINEPHRINE; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; WEIGHT GAIN;

MLCS; MLOWN;

EID: 84874643708     PISSN: 20900708     EISSN: 20900716     Source Type: Journal    
DOI: 10.1155/2013/457047     Document Type: Article

References (39)

1. Ginsberg H. N., Maccallum P. R., The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. Journal of the CardioMetabolic Syndrome 2009 4 2 113 119 2-s2.0-65349195631 10.1111/j.1559-4572.2008.00044.x
2. Szczepanska-Sadowska E., Cudnoch-Jedrzejewska A., Ufnal M., Zera T., Brain and cardiovascular diseases: common neurogenic background of cardiovascular, metabolic and inflammatory diseases. Journal of Physiology and Pharmacology 2010 61 509 521
3. Ahlskog J. E., Hoebel B. G., Overeating and obesity from damage to a noradrenergic system in the brain. Science 1973 182 4108 166 169 2-s2.0-0015810308
4. Kasparov S., Teschemacher A. G., Altered central catecholaminergic transmission and cardiovascular disease. Experimental Physiology 2008 93 6 725 740 2-s2.0-43549089723 10.1113/expphysiol.2007.041814 (Pubitemid 351678598)
5. Rinaman L., Hindbrain noradrenergic A2 neurons: diverse roles in autonomic, endocrine, cognitive, and behavioral functions. American Journal of Physiology 2011 300 2 R222 R235 2-s2.0-79551566749 10.1152/ajpregu.00556.2010
6. Ritter S., Pelzer N. L., Ritter R. C., Absence of glucoprivic feeding after stress suggests impairment of noradrenergic neuron function. Brain Research 1978 149 2 399 411 2-s2.0-0018141767 10.1016/0006-8993(78)90483-3 (Pubitemid 8356896)
7. Valentino R. J., Curtis A. L., Page M. E., Pavcovich L. A., Florin-Lechner S. M., Activation of the locus ceruleus brain noradrenergic system during stress: circuitry, consequences, and regulation. Advances in Pharmacology 1998 42 781 784 2-s2.0-0031982431
8. Bello N. T., Zahner M. R., Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Current Opinion in Investigational Drugs 2009 10 10 1105 1116 2-s2.0-70349739420
9. Heal D. J., Gosden J., Smith S. L., What is the prognosis for new centrally-acting anti-obesity drugs? Neuropharmacology 2012 63 132 146
10. Rothman R. B., Hendricks E. J., Phentermine cardiovascular safety. American Journal of Emergency Medicine 2009 27 8 1010 1013 2-s2.0-70349165358 10.1016/j.ajem.2009.07.014
11. Rucker D., Padwal R., Li S. K., Curioni C., Lau D. C. W., Long term pharmacotherapy for obesity and overweight: updated meta-analysis. British Medical Journal 2007 335 7631 1194 1199 2-s2.0-37249083878 10.1136/bmj.39385. 413113.25 (Pubitemid 350273303)
12. Lemberger L., Terman S., Rowe H., Billings R., The effect of nisoxetine (Lilly compound 94939), a potential antidepressant, on biogenic amine uptake in man. British Journal of Clinical Pharmacology 1976 3 2 215 220 2-s2.0-0017254866
13. Wong D. T., Bymaster F. P., The comparison of fluoxetine and nisoxetine with tricyclic antidepressants in blocking the neurotoxicity of p chloroamphetamine and 6 hydroxydopamine in the rat brain. Research Communications in Chemical Pathology and Pharmacology 1976 15 2 221 231 2-s2.0-0017138672
14. Cheetham S. C., Viggers J. A., Butler S. A., Prow M. R., Heal D. J., [3H]nisoxetine-a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments. Neuropharmacology 1996 35 1 63 70 2-s2.0-0029670751 10.1016/0028-3908(95)00134-4
15. Kelwala S., Stanley M., Gershon S., History of antidepressants: successes and failures. Journal of Clinical Psychiatry 1983 44 5 40 48 2-s2.0-0020622191 (Pubitemid 13088834)
16. Belej T., Manji D., Sioutis S., Barros H. M. T., Nobrega J. N., Changes in serotonin and norepinephrine uptake sites after chronic cocaine: pre- vs. post-withdrawal effects. Brain Research 1996 736 1-2 287 296 2-s2.0-0030583644 10.1016/0006-8993(96)00713-5 (Pubitemid 26356487)
17. Tella S. R., Effects of monoamine reuptake inhibitors on cocaine self-administration in rats. Pharmacology Biochemistry and Behavior 1995 51 4 687 692 2-s2.0-0029042534 10.1016/0091-3057(94)00438-O
18. Billes S. K., Cowley M. A., Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice. Neuropsychopharmacology 2007 32 4 822 834 2-s2.0-33947232740 10.1038/sj.npp.1301155 (Pubitemid 46426174)
19. Jackson H. C., Needham A. M., Hutchins L. J., Mazurkiewicz S. E., Heal D. J., Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. British Journal of Pharmacology 1997 121 8 1758 1762 2-s2.0-0030860731 10.1038/sj.bjp.0701312 (Pubitemid 27343407)
20. Billes S. K., Cowley M. A., Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis. Neuropsychopharmacology 2008 33 6 1287 1297 2-s2.0-42049116096 10.1038/sj.npp.1301526 (Pubitemid 351521727)
21. Thomas G. H., Babbs A. J., Chatfield R. E., Krülle T. M., Widdowson P. S., Provost D., McCormack J. G., 5-HT1A activation counteracts cardiovascular but not hypophagic effects of sibutramine in rats. Obesity 2009 17 3 467 473 2-s2.0-60849111422 10.1038/oby.2008.550
22. Abolfathi Z., Couture J., Vallée F., LeBel M., Tanguay M., Masson E., A pilot study to evaluate the pharmacokinetics of sibutramine in healthy subjects under fasting and fed conditions. Journal of Pharmacy and Pharmaceutical Sciences 2004 7 3 345 349 2-s2.0-27444443769 (Pubitemid 41528885)
23. Noh K., Bae K., Min B., Kim E., Kwon K. I., Jeong T., Kang W., Enantioselective pharmacokinetics of sibutramine in rat. Archives of Pharmacal Research 2010 33 2 267 273 2-s2.0-77949885683 10.1007/s12272-010-0212-7
24. Levin B. E., Sympathetic activity, age, sucrose preference, and diet-induced obesity. Obesity Research 1993 1 4 281 287 2-s2.0-0001203780
25. Levin B. E., Reduced paraventricular nucleus norepinephrine responsiveness in obesity-prone rats. American Journal of Physiology 1996 270 2 R456 R461 2-s2.0-0029947389
26. Levin B. E., Dunn-Meynell A. A., Maternal obesity alters adiposity and monoamine function in genetically predisposed offspring. American Journal of Physiology 2002 283 5 R1087 R1093 2-s2.0-0036838623 (Pubitemid 35216983)
27. Bello N. T., Guarda A. S., Terrillion C. E., Redgrave G. W., Coughlin J. W., Moran T. H., Repeated binge access to a palatable food alters feeding behavior, hormone profile, and hindbrain c-Fos responses to a test meal in adult male rats. American Journal of Physiology 2009 297 3 R622 R631 2-s2.0-69249158156 10.1152/ajpregu.00087.2009
28. Paxinos G., Watson C., The Rat Brain in Stereotaxic Coordinatesed 1998 4th San Diego, Calif, USA Academic Press
29. Overton J. M., Williams T. D., Chambers J. B., Rashotte M. E., Cardiovascular and metabolic responses to fasting and thermoneutrality are conserved in obese Zucker rats. American Journal of Physiology 2001 280 4 R1007 R1015 2-s2.0-0035008129
30. Woolard J., Bennett T., Dunn W. R., Heal D. J., Aspley S., Gardiner S. M., Acute cardiovascular effects of sibutramine in conscious rats. Journal of Pharmacology and Experimental Therapeutics 2004 308 3 1102 1110 2-s2.0-1342323321 10.1124/jpet.103.061259 (Pubitemid 38263987)
31. Birkenfeld A. L., Schroeder C., Boschmann M., Tank J., Franke G., Luft F. C., Biaggioni I., Sharma A. M., Jordan J., Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 2002 106 19 2459 2465 2-s2.0-0037027498 10.1161/01.CIR.0000036370.31856.73 (Pubitemid 35278802)
32. Schroeder C., Tank J., Boschmann M., Diedrich A., Sharma A. M., Biaggioni I., Luft F. C., Jordan J., Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation 2002 105 3 347 353 2-s2.0-0037154309 10.1161/hc0302.102597 (Pubitemid 34106184)
33. Miyata S., Hamamura T., Lee Y., Miki M., Habara T., Oka T., Endo S., Taoka H., Kuroda S., Contrasting Fos expression induced by acute reboxetine and fluoxetine in the rat forebrain: neuroanatomical substrates for the antidepressant effect. Psychopharmacology 2005 177 3 289 295 2-s2.0-12344268894 10.1007/s00213-004-2072-7 (Pubitemid 40137289)
34. Schwartz M. W., Woods S. C., Porte D. Jr., Seeley R. J., Baskin D. G., Central nervous system control of food intake. Nature 2000 404 6778 661 671 2-s2.0-0034611732 (Pubitemid 30205071)
35. Kang Y. M., Ouyang W., Chen J. Y., Qiao J. T., Dafny N., Norepinephrine modulates single hypothalamic arcuate neurons via α 1and β adrenergic receptors. Brain Research 2000 869 1-2 146 157 2-s2.0-0034733977 10.1016/S0006-8993(00)02380-5 (Pubitemid 30345785)
36. Fraley G. S., Ritter S., Immunolesion of norepinephrine and epinephrine afferents to medial hypothalamus alters basal and 2-deoxy-D-glucose-induced neuropeptide Y and agouti gene-related protein messenger ribonucleic acid expression in the arcuate nucleus. Endocrinology 2003 144 1 75 83 2-s2.0-0037227401 10.1210/en.2002-220659 (Pubitemid 36076095)
37. Levin B. E., Reduced norepinephrine turnover in organs and brains of obesity-prone rats. American Journal of Physiology 1995 268 2 R389 R394 2-s2.0-0028961718
38. Levin B. E., Triscari J., Sullivan A. C., The effect of diet and chronic obesity on brain catecholamine turnover in the rat. Pharmacology Biochemistry and Behavior 1986 24 2 299 304 2-s2.0-0022631735 (Pubitemid 16185597)
39. FDA, Guidance for the clinical evaluation of weight-control drugs. Critical Reviews in Food Science and Nutrition 2001 41 91 94